

REMARKS

Claims 1-11, 14-86, 89, and 117-127 are allowed.

The present amendment is submitted to correct a typographical error in Claim 117. As described in the specification at page 23, lines 19-26, the composition recited in that claim contains a P2Y2 receptor agonist. Claim 117 has been amended to properly recite that component. Since the Claim 1 is patentable and Claim 117 depends from Claim 1, there is no issue regarding the patentability of the claim after entry of the amendment. The amendment was not submitted previously because Applicants have only just become aware of the error.


No new matter is believed to have been added to this application by the amendment submitted above.

Since the amendments relate to formal matters only, no additional search and examination is believed to be necessary. Accordingly, entry thereof is respectfully requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon

Customer Number  
**22850**



---

James J. Kelly, Ph.D.  
Registration No. 41,504